



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	176365	METAGENICS LAXATONE
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Metagenics (Aust) Pty Ltd	
<b>Postal Address</b>	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
<b>ARTG Start Date</b>	6/10/2010	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . METAGENICS LAXATONE

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	25/01/2020
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

- Traditionally used in Western herbal medicine to decrease/reduce/relieve constipation
- Traditionally used in Western herbal medicine to stimulant laxative
- Traditionally used in Western herbal medicine to maintain/support bowel regularity
- Traditionally used in Western herbal medicine to decrease/reduce/relieve flatulence/carminative
- Traditionally used in Western herbal medicine to maintain/support healthy digestion
- Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of indigestion/dyspepsia
- Traditionally used in Western herbal medicine to decrease/reduce/relieve gastrointestinal pain
- Traditionally used in Western herbal medicine to decrease/reduce/relieve digestive spasms
- Traditionally used in Western herbal medicine to helps enhance/improve/promote/increase bile secretion/flow

### Indication Requirements

- Product presentation must not refer to or imply weight loss.
- Product presentation must not imply or refer to gastro oesophageal reflux disease.
- Label statement for stimulant laxatives: Prolonged use may cause serious bowel problems.
- Label statement: If symptoms persist, talk to your health professional.
- Label statement: Drink plenty of water (or words to that effect).
- Label statement: Do not use when abdominal pain, nausea or vomiting are present or if you develop diarrhoea. If you are pregnant or breastfeeding - seek the advice of a healthcare professional before taking this product (or words to that effect).

### Standard Indications



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

Drink plenty of water (or words to that effect).

Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product (or words to that effect).

Prolonged use may cause serious bowel problems.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Use in children under 12 years is not recommended.

**Additional Product information**

**Pack Size/Poison information**

Pack Size	Poison Schedule
-----------	-----------------

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Cinnamomum cassia</b>	<b>31.25 mg</b>
<b>Frangula purshiana stem bark Extract dry concentrate</b>	<b>100 mg</b>
Equivalent: Frangula purshiana (Dry)	400 mg
<b>Matricaria chamomilla flower Extract dry concentrate</b>	<b>83.33 mg</b>
Equivalent: Matricaria chamomilla (Dry)	500 mg
<b>Rheum officinale root Extract dry concentrate</b>	<b>25 mg</b>
Equivalent: Rheum officinale (Dry)	250 mg
<b>Zingiber officinale rhizome Extract dry concentrate</b>	<b>100 mg</b>
Equivalent: Zingiber officinale (Dry)	500 mg

**Other Ingredients (Excipients)**

calcium hydrogen phosphate dihydrate

colloidal anhydrous silica

disodium edetate

gellan gum

hypromellose

magnesium stearate

microcrystalline cellulose

potable water

potassium acetate

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.